Chew Emily Y, Clemons Traci E, Harrington Molly, Bressler Susan B, Elman Michael J, Kim Judy E, Garfinkel Richard, Heier Jeffrey S, Brucker Alexander, Boyer David
*Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bethesda, Maryland; †The EMMES Corporation, Rockville, Maryland; ‡The Retina Division at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland; §Elman Retina Group, Baltimore, Maryland; ¶Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin; **Retina Group of Washington, Washington, D.C.; ††Ophthalmic Consultants of Boston, Boston, Massachusetts; ‡‡Scheie Eye Institute, Philadelphia, Pennsylvania; §§Retina-Vitreous Associates Medical Group, Los Angeles, California.
Retina. 2016 Aug;36(8):1542-7. doi: 10.1097/IAE.0000000000000940.
To determine the effectiveness of different monitoring modalities to detect incident neovascularization associated with age-related macular degeneration (AMD).
Secondary analyses compared the rates of detecting incident neovascular AMD in prescheduled office visits versus office visits triggered by monitoring device or by symptom realization in a randomized trial evaluating home telemonitoring device plus standard care (device arm) versus standard care alone.
At prescheduled office visits, neovascular AMD was detected in 14/1927 visits (0.7%, 95% confidence interval [CI]: 0.4%-1.1%) and 14/1949 visits (0.7%, 95% CI: 0.3%-1.1%) in the device and standard care alone arms, respectively. Thirty-seven participants with neovascular AMD were detected in 318 office visits (11.6%, 95% CI: 8.1%-15.2%) triggered by device or symptom realization and 17 neovascular AMD in 65 office visits (26%, 95% CI: 15.5%-36.8%) triggered by symptom realization in the device and standard care alone arms, respectively. The home device strategy had a higher neovascular-AMD detection rate than prescheduled office visits (relative risk = 16.0 [95% CI: 8.8-29.3]). Neovascular AMD detected at triggered visits were associated with less vision loss from baseline in the device arm versus standard care alone arm (-3 letters vs. -11.5 letters, respectively, P = 0.03).
Telemonitoring may alter the management of patients with AMD and improve vision outcomes.
确定不同监测方式检测与年龄相关性黄斑变性(AMD)相关的新生血管形成的有效性。
在一项随机试验中,对预定门诊就诊与由监测设备触发或症状出现触发的门诊就诊中检测新生血管性AMD的比率进行二次分析,该试验评估了家庭远程监测设备加标准护理(设备组)与单独标准护理的效果。
在预定门诊就诊时,设备组和单独标准护理组中分别有14/1927次就诊(0.7%,95%置信区间[CI]:0.4%-1.1%)和14/1949次就诊(0.7%,95%CI:0.3%-1.1%)检测到新生血管性AMD。在由设备或症状出现触发的318次门诊就诊中,检测到37例新生血管性AMD患者(11.6%,95%CI:8.1%-15.2%);在单独标准护理组中,由症状出现触发的65次门诊就诊中有17例新生血管性AMD(26%,95%CI:15.5%-36.8%)。家庭设备策略的新生血管性AMD检测率高于预定门诊就诊(相对风险=16.0[95%CI:8.8-29.3])。与单独标准护理组相比,在设备组中,由触发就诊检测到的新生血管性AMD与基线视力丧失较少相关(分别为-3字母对-11.5字母,P=0.03)。
远程监测可能会改变AMD患者的管理方式并改善视力预后。